Literature DB >> 18237549

Insulin-like growth factor I (CA) repeats are associated with higher melanoma's Breslow index but not associated with the presence of the melanoma. A pilot study.

Concetta Santonocito1, Andrea Paradisi, Rodolfo Capizzi, Paola Concolino, Maria Michela Lavieri, Sara Lanza Silveri, Daniele De Luca, Caterina Catricalà, Aldo Di Carlo, Cecilia Zuppi, Franco Ameglio, Ettore Capoluongo.   

Abstract

BACKGROUND: IGF-I-(CA) repeats have been previously analysed in few types of cancer and the results, although discordant in different studies, showed possible associations between cancer and IGF-I(CA)(19) repeats. Aim of this pilot study was to detect a possible association between some of the IGF-I(CA) repeats and the presence of malignant melanoma and its Breslow index.
METHODS: Two hundred patients affected with cutaneous malignant melanoma and 100 control healthy subjects were analysed for IGF-I(CA) repeats by fragment analysis sequencing and, partially, confirmed by direct sequencing.
RESULTS: A significant association of IGF-I(CA)(19) repeats was observed with melanoma higher Breslow indices (P<0.001), while no association between melanoma patients and the different genotypes of IGF-I(CA) was found. The above mentioned association was confirmed after Bonferroni's correction for multiple comparisons and also by logistic regression analysis adjusted for age, sex and BMI variables. A slight, significant difference (P=0.03) was observed for serum IGF-I values in IGF-I(CA)(19)-positive or IGF-I(CA)(19)-negative subjects. DISCUSSION: The association observed for IGF-I(CA)(19) and malignant melanoma is in keeping with similar results obtained in prostate or breast cancers, suggesting that this type of repeat may be directly or indirectly important in controlling cancer induction and its severity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237549     DOI: 10.1016/j.cca.2008.01.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  Insulin-like growth factor system and sporadic malignant melanoma.

Authors:  Ettore Capoluongo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

2.  Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma.

Authors:  Sungshim Lani Park; Veronica Wendy Setiawan; Peter A Kanetsky; Zuo-Feng Zhang; Lynne R Wilkens; Laurence N Kolonel; Loïc Le Marchand
Journal:  Cancer Causes Control       Date:  2011-06-23       Impact factor: 2.506

Review 3.  Body Mass Index and Melanoma Prognosis.

Authors:  Nicoletta Cassano; Stefano Caccavale; Gino A Vena; Giuseppe Argenziano
Journal:  Dermatol Pract Concept       Date:  2021-09-01

4.  Circulating insulin-like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition.

Authors:  Kathryn E Bradbury; Paul N Appleby; Sarah J Tipper; Ruth C Travis; Naomi E Allen; Marina Kvaskoff; Kim Overvad; Anne Tjønneland; Jytte Halkjaer; Iris Cervenka; Yahya Mahamat-Saleh; Fabrice Bonnet; Rudolf Kaaks; Renée T Fortner; Heiner Boeing; Antonia Trichopoulou; Carlo La Vecchia; Alexander J Stratigos; Domenico Palli; Sara Grioni; Giuseppe Matullo; Salvatore Panico; Rosario Tumino; Petra H Peeters; H Bas Bueno-de-Mesquita; Reza Ghiasvand; Marit B Veierød; Elisabete Weiderpass; Catalina Bonet; Elena Molina; José M Huerta; Nerea Larrañaga; Aurelio Barricarte; Susana Merino; Karolin Isaksson; Tanja Stocks; Ingrid Ljuslinder; Oskar Hemmingsson; Nick Wareham; Kay-Tee Khaw; Marc J Gunter; Sabina Rinaldi; Konstantinos K Tsilidis; Dagfinn Aune; Elio Riboli; Timothy J Key
Journal:  Int J Cancer       Date:  2018-12-07       Impact factor: 7.396

5.  Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.

Authors:  Claudia Greco; Gaetano Vitelli; Giuseppe Vercillo; Rosa Vona; Diana Giannarelli; Isabella Sperduti; Francesco Pisani; Ettore Capoluongo; Maria Concetta Petti; Franco Ameglio
Journal:  J Exp Clin Cancer Res       Date:  2009-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.